Telix Pharmaceuticals (TLPPF) Accumulated Expenses (2023 - 2026)

Telix Pharmaceuticals (TLPPF) has reported Accumulated Expenses for 4 consecutive years, with $607000.0 the latest figure, recorded in Q2 2026.

• On a quarterly basis, Accumulated Expenses changed N/A year-over-year to $607000.0 in Q2 2026; TTM through Jun 2026 was $607000.0, a N/A change from a year earlier, with the FY2025 full-year figure at $444000.0, up 45.1% from the prior year.
• Accumulated Expenses was $607000.0 for Q2 2026 at Telix Pharmaceuticals, up from $444000.0 in the prior quarter.
• Over five years, Accumulated Expenses peaked at $607000.0 in Q2 2026 and troughed at $214826.9 in Q4 2023.
• A 4-year average of $397710.8 and a median of $384508.2 in 2025 frame the typical range for Accumulated Expenses.
• Across the five-year window, Accumulated Expenses jumped 51.29% in 2024 and jumped 36.61% in 2025, its largest moves.
• Over 4 years, Accumulated Expenses stood at $214826.9 in 2023, then jumped by 51.29% to $325016.4 in 2024, then jumped by 36.61% to $444000.0 in 2025, then jumped by 36.71% to $607000.0 in 2026.
• The last three Accumulated Expenses figures came in at $607000.0 (Q2 2026), $444000.0 (Q4 2025), and $325016.4 (Q4 2024), per Business Quant data.